This Article Full Text Full Text (PDF) All Versions of this Article: 51/3/734    most recent HYPERTENSIONAHA.107.104299v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imanishi, T. Articles by Akasaka, T. Search for Related Content PubMed PubMed Citation Articles by Imanishi, T. Articles by Akasaka, T. Related Collections ACE/Angiotension receptors Endothelium/vascular type/nitric oxide Related Article

(Hypertension. 2008;51:734.)
© 2008 American Heart Association, Inc.

Original Articles

Addition of Eplerenone to an Angiotensin-Converting Enzyme Inhibitor Effectively Improves Nitric Oxide Bioavailability

Toshio Imanishi; Hideyuki Ikejima; Hiroto Tsujioka; Akio Kuroi; Katsunobu Kobayashi; Yasuteru Muragaki; Seiichi Mochizuki; Masami Goto; Kiyoshi Yoshida; Takashi Akasaka

From the Departments of Cardiovascular Medicine (T.I., H.I., H.T., A.K., K.K., T.A.) and Pathology (Y.M.), Wakayama Medical University, Wakayama, Japan; and the Department of Medical Engineering (S.M., M.G.) and Division of Cardiology (K.Y.), Kawasaki Medical School, Okayama, Japan.

Correspondence Toshio Imanishi, Department of Cardiovascular Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama 641-8510, Japan. E-mail t-imani{at}wakayama-med.ac.jp

Angiotensin II and aldosterone both promote endothelial dysfunction and atherosclerosis. We investigated the effect of a combination of eplerenone, a selective aldosterone antagonist, and enalapril, an angiotensin-converting enzyme inhibitor, on NO bioavailability and spontaneous atherosclerotic changes. Twenty-four myocardial infarction–prone Watanabe heritable hyperlipidemic rabbits were treated with vehicle (control), eplerenone (50 mg/kg per day), enalapril (3 mg/kg per day), or eplerenone plus enalapril for 8 weeks (n=6 in each group). After treatment, acetylcholine-induced NO production was measured as a surrogate for endothelium-protective function, and vascular peroxynitrite (a product of superoxide and NO) was measured to assess dysfunctional endothelial NO synthase activity. Plaque area was quantified by histology. Intra-aortic infusion of acetylcholine produced an increase in plasma NO concentration that was significantly higher with all of the drug treatments compared with the control. Eplerenone and enalapril, in combination, increased acetylcholine-induced NO by 7.9 nM, which was significantly higher than with either eplerenone or enalapril alone. Vascular peroxynitrite was significantly higher in the control group (1.3 pmol/mg of protein) and significantly lower with combination treatment (0.4 pmol/mg of protein) compared with the enalapril or eplerenone group. The highest tetrahydrobiopterin levels were observed after cotreatment with eplerenone and enalapril. Histology of the thoracic aorta showed a significantly decreased plaque area with combination therapy compared with monotherapy. Combined treatment with a selective aldosterone antagonist and an angiotensin-converting enzyme inhibitor has additive protective effects on endothelial function and on atherosclerotic changes via decreased nitrosative stress.

Key Words: NO • endothelial function • aldosterone • nitrosative stress

Related Article:

More NO-No More ROS: Combined Selective Mineralocorticoid Receptor Blockade and Angiotensin-Converting Enzyme Inhibition for Vascular Protection

Johann Bauersachs and Daniela Fraccarollo
Hypertension 2008 51: 624-625. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				M. Dunkel, S. Gunther, J. Ahmed, B. Wittig, and R. Preissner SuperPred: drug classification and target prediction Nucleic Acids Res., July 1, 2008; 36(suppl_2): W55 - W59. [Abstract] [Full Text] [PDF]

				J. Bauersachs and D. Fraccarollo More NO-No More ROS: Combined Selective Mineralocorticoid Receptor Blockade and Angiotensin-Converting Enzyme Inhibition for Vascular Protection Hypertension, March 1, 2008; 51(3): 624 - 625. [Full Text] [PDF]